Treatment of Ventricular Arrhythmias—Suppression, Survival, and the Problem of Bias

  1. BRIAN MCGOVERN, M.B.;
  2. HASAN GARAN, M.D.; and
  3. JEREMY N. RUSKIN, M.D.
  1. Massachusetts General Hospital;
    Boston, Massachusetts

    Excerpt

    Various innovative drug, surgical, and electrical treatments have been used recently for patients with ventricular tachyarrhythmias (1-8). Each approach has enthusiastic advocates who compare studies and attribute fewer recurrent arrhythmias or improved survival to a particular treatment. However, no adequate comparative studies between these therapies have been done. Furthermore, because of ethical and practical constraints, randomized placebo-controlled studies that may approximate an ideal comparison may never be done for some of these therapies (9). Because of reports of promising, albeit uncontrolled, data, many physicians are understandably reluctant to withhold a particular treatment from a patient considered to be at high

    This 100-word excerpt has been provided in the absence of an abstract.

    Acknowledgments

    ACKNOWLEDGMENTS: Grant support: in part by Grant RO1 HL25992 from the National Institutes of Health. Dr. Ruskin is the recipient of an American Heart Association Established Investigatorship (E181-177).

    « Previous | Next Article »Table of Contents